UCB's new meds spur sales growth; Otsuka nabs NICE backing for kidney med;

> Belgium's UCB hiked its full-year financial outlook on strong growth of three of its new drugs--Cimzia, Vimpat and Neupro--and ongoing sales of its off-patent epilepsy med Keppra. Report

> Otsuka's Jinarc, a treatment for autosomal dominant polycystic kidney disease, won backing from England's cost-effectiveness watchdogs. Report

> Merck & Co. ($MRK) said its price cut on Remicade in the U.K. will save England's National Health Service millions of pounds. Report

And Finally... More than three-fourths of Americans say the cost of prescription drugs for serious diseases is their chief health concern, a Kaiser Family Foundation poll found. Report

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.